Acticor Biotech krijgt kapitaalinjectie van 1,4 miljoen euro
PARIJS–(BUSINESS WIRE)– Acticor Biotech, een biotechnologiebedrijf in anti-trombotica zonder risico op bloedingen bij noodbehandeling van ischemische beroertes, heeft een kapitaalverhoging van 1,4 miljoen euro afgerond. De financiering werd deels via het crowdfundingplatform Anaxago opgehaald (740.000 euro) en kwam van de onderzoeksorganisatie ARMESA (500.000 euro) en business angels.
Het kandidaatsmedicijn ACT-017 staat voor een grote vernieuwing van noodhulp bij ischemische beroertes. Het is een tot nu toe unieke kandidaat dat een nieuwe doelwit remt, het eiwit glycoproteïne VI. Dit eiwit is verantwoordelijk voor de aanwas van bloedpropjes bij een beroerte. ACT-017 is bedoeld voor apart gebruik, of in combinatie met Alteplase®, het enige noodmedicijn dat op dit moment beschikbaar is. Dit medicijn wordt aan minder dan 10 procent van de patiënten toegediend in de eerste vierenhalf uur na de eerste symptomen van een beroerte.
€1.4 Million Capital Increase by Acticor Biotech |
|||||
|
PARIS–(BUSINESS WIRE)– Acticor Biotech, biotechnology company which is developing an anti-thrombotic agent without bleeding risk for the emergency treatment of ischemic strokes, has just completed a €1.4 million capital increase. The funds were raised from investors via the Anaxago crowdfunding platform (€740,000), from research association ARMESA (€500,000) and from business angels (€170,000). Acticor Biotech’s ACT-017 drug candidate represents a major innovation in the emergency treatment of ischemic strokes. It is a first-in-class candidate that inhibits a new target protein, the glycoprotein VI, which is specifically responsible for the growth of blood clots during a stroke. ACT-017 is intended to be used alone or in combination with Alteplase®, the only emergency treatment currently available, which is given to fewer than 10% of patients in the four and a half hours after the first symptoms appearing. The capital increase will enable Acticor Biotech to continue pre-clinical development and produce initial batches of ACT-017. Gilles Avenard, CEO of Acticor Biotech, said “the emergency treatment of ischemic strokes represents a major medical need, since over 600,000 patients per year are affected in Europe. The treatment of ischemic strokes, either in combination with Alteplase® or after Alteplase®, must be without bleeding risk. In vitro and in vivo testing of ACT-017 have confirmed results already published, suggesting that we have a drug candidate that will eventually be possible to admin just after the first symptoms appear.” Joachim Dupont, co-founder of Anaxago and director of Acticor Biotech, said “this second funding round for Acticor Biotech, organized via our platform, is 30% larger than the first round and provides further validation of the crowdfunding model for the healthcare sector. It shows the interest of investors for Acticor biotech developments in stroke treatment, and their desire to support the development of innovative solutions to major unresolved public health problems.” According to the WHO, 23 million people around the world will suffer a stroke in 2030. About Ischemic stroke – http://acticor-biotech.com/en/stroke/ About ACT-017 – http://acticor-biotech.com/en/technology/ About ACTICOR-BIOTECH – http://acticor-biotech.com/ View source version on businesswire.com: http://www.businesswire.com/news/home/20160711005765/en/ Contacts Acticor Biotech |
|||||